Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
Merck
Mallinckrodt
McKesson

Last Updated: August 19, 2022

Amphastar Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for AMPHASTAR PHARMS INC, and what generic and branded alternatives to AMPHASTAR PHARMS INC drugs are available?

AMPHASTAR PHARMS INC has eleven approved drugs.



Summary for Amphastar Pharms Inc
US Patents:0
Tradenames:10
Ingredients:10
NDAs:11

Drugs and US Patents for Amphastar Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amphastar Pharms Inc NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 209933-001 Sep 25, 2017 AP RX No No See Plans and Pricing See Plans and Pricing
Amphastar Pharms Inc SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 209832-001 Dec 18, 2017 DISCN No No See Plans and Pricing See Plans and Pricing
Amphastar Pharms Inc DUOCAINE bupivacaine hydrochloride; lidocaine hydrochloride INJECTABLE;INJECTION 021496-001 May 23, 2003 DISCN No No See Plans and Pricing See Plans and Pricing
Amphastar Pharms Inc NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 209933-002 Sep 25, 2017 AP RX No No See Plans and Pricing See Plans and Pricing
Amphastar Pharms Inc GANIRELIX ACETATE ganirelix acetate INJECTABLE;INJECTION 212613-001 Apr 7, 2022 AP RX No No See Plans and Pricing See Plans and Pricing
Amphastar Pharms Inc SUCCINYLCHOLINE CHLORIDE succinylcholine chloride INJECTABLE;INJECTION 213432-001 Jun 8, 2020 DISCN No No See Plans and Pricing See Plans and Pricing
Amphastar Pharms Inc ISOPROTERENOL HYDROCHLORIDE isoproterenol hydrochloride INJECTABLE;INJECTION 210106-001 Jun 18, 2018 AP RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for AMPHASTAR PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 250 mcg/0.5 mL, 1 mL PFS ➤ Subscribe 2012-03-30
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Baxter
Moodys
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.